BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year revenue growth rate
3Y CAGR
+216.2%/yr
vs -37.5%/yr prior
Acceleration
+253.7pp
Accelerating
Percentile
P87
Within normal range
vs 3Y Ago
31.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 155.06% |
| Q3 2025 | -2.42% |
| Q2 2025 | 12.24% |
| Q1 2025 | 10.64% |
| Q4 2024 | 12.34% |
| Q3 2024 | 7.09% |
| Q2 2024 | 17.86% |
| Q1 2024 | -0.69% |
| Q4 2023 | 7.68% |
| Q3 2023 | 5.15% |
| Q2 2023 | 19.94% |
| Q1 2023 | -13.54% |
| Q4 2022 | 4.90% |
| Q3 2022 | 15.71% |
| Q2 2022 | 31.27% |
| Q1 2022 | 5.86% |
| Q4 2021 | 15.04% |
| Q3 2021 | -17.94% |
| Q2 2021 | 162.13% |
| Q1 2021 | 374.58% |
| Q4 2020 | -34.19% |
| Q3 2020 | 112.54% |
| Q2 2020 | -40.47% |
| Q1 2020 | -87.86% |
| Q4 2019 | 2138.03% |
| Q3 2019 | 22.58% |
| Q2 2019 | -75.40% |
| Q1 2019 | 115.72% |
| Q4 2018 | 87.69% |
| Q3 2018 | -88.36% |
| Q2 2018 | 214.24% |
| Q1 2018 | 2.21% |
| Q4 2017 | -55.59% |
| Q3 2017 | 182.67% |
| Q2 2017 | -67.16% |
| Q1 2017 | 5.05% |
| Q4 2016 | 15.72% |
| Q3 2016 | 62.17% |
| Q2 2016 | -0.68% |
| Q1 2016 | 4.74% |